Report Highlights

Ventilators in the United States: Market Overview

The United States is the largest ventilator market in the world by revenue, and its structure departs from the global norm. Hospital intensive care capacity, deep reimbursement pools and a dense base of registered respiratory therapists support high-specification purchasing that emerging markets rarely match. Buying runs through hospital capital budgets, group purchasing organizations and integrated delivery networks rather than central government tenders, so demand is driven by replacement and upgrade cycles, typically seven to ten years for ICU units.

The market is valued at USD 1.42 billion in 2024, well below the global figure because most installed ventilators worldwide sit in Asia and Europe at lower price points. U.S. buyers pay premiums for closed-loop monitoring, connectivity with electronic health records and remote device management. Home ventilation, supplied largely for chronic neuromuscular and COPD patients, adds a second revenue stream that global aggregate figures tend to underweight.

Growth Drivers for U.S. Ventilators

Demographics provide the most durable driver. Census Bureau estimates place residents aged 65 and older at roughly 18 percent of the population, and CDC data show more than 16 million adults carry a COPD diagnosis. These patients drive sustained non-invasive ventilation demand in acute and home settings. Medicare coverage for home ventilators under the Durable Medical Equipment benefit, administered by CMS through Medicare Part B, anchors recurring revenue for home-care suppliers such as Lincare and AdaptHealth.

Hospital infrastructure and preparedness spending supply the second and third drivers. Hospitals are replacing pandemic-era surge units with platforms that meet Section 524B of the Federal Food, Drug, and Cosmetic Act, which requires cybersecurity documentation for connected devices. Separately, the Strategic National Stockpile, managed by the Administration for Strategic Preparedness and Response, maintains ventilator reserves under PAHPA authority, sustaining a baseline of federal procurement even without a declared emergency.

Market Restraints and Entry Barriers

Regulatory clearance is the first barrier. Continuous ventilators are Class II devices under 21 CFR 868.5895, requiring a 510(k) premarket notification, and manufacturers must align quality systems with the Quality Management System Regulation, which becomes effective on February 2, 2026. Tariff exposure is rising because the Commerce Department's Section 232 investigation into medical devices, launched in 2025, targets duties on imported components and finished units.

Incumbent advantage compounds clearance risk. Hospitals buy through multi-year contracts negotiated by Vizient and Premier, which lock in pricing and service terms for established vendors such as Medtronic and Getinge. Respiratory therapists must be trained on each platform, so switching costs extend beyond the device itself. Medicare inpatient payments do not reimburse ventilator purchases separately, so hospitals fund capital from operating margins, lengthening sales cycles.

Market Opportunities in U.S. Ventilators

Home ventilation is the nearest-term opening. Under its 2024 consent decree with the Department of Justice and the FDA, Philips Respironics is restricted from selling new sleep and respiratory devices in the United States until compliance milestones are met, freeing patient and supplier relationships for competitors. Analyst estimates place the addressable U.S. home ventilation replacement pool at roughly USD 420 million annually, accessible through Medicare-enrolled durable medical equipment channels.

Rural hospitals form the second opportunity. Roughly 1,300 Critical Access Hospitals operate under CMS cost-based reimbursement, and many still rely on units purchased before 2020. Transport ventilators for emergency medical services and interfacility transfers form a further niche, with an estimated USD 150 million addressable annually across state EMS agencies. Entrants offering leasing and service-inclusive contracts can bypass the capital constraints that slow rural purchasing.

Market at a Glance

Leading Market Participants

• Medtronic
• Philips Respironics
• ResMed
• Getinge
• Dräger
• Hamilton Medical
• Vyaire Medical
• Ventec Life Systems
• Mindray
• ICU Medical

Regulatory and Policy Environment

The FDA's Center for Devices and Radiological Health regulates ventilators through 21 CFR Part 868 and the 510(k) pathway, with Medical Device User Fee Amendments setting a 90-FDA-day review goal. Connected units must meet Section 524B cybersecurity requirements, and manufacturers must supply software bill-of-materials documentation at submission. Quality systems must meet QMSR requirements by February 2, 2026, aligning U.S. practice with ISO 13485.

Reimbursement and preparedness policy sit with CMS and ASPR. CMS administers Medicare Part B coverage for home ventilators under the Durable Medical Equipment benefit and Medicare inpatient payments under the Inpatient Prospective Payment System. ASPR manages the Strategic National Stockpile under the Pandemic and All-Hazards Preparedness Act, while Defense Production Act Title III supports domestic capacity. Federal procurement follows the Trade Agreements Act.

Long-Term Outlook for U.S. Ventilators

By 2032 the U.S. ventilator market is forecast to reach USD 2.23 billion at a CAGR of 5.8 percent, with growth concentrated in home and non-hospital settings. Hospital ICU units will remain the largest revenue pool, but their share will edge down as home ventilation expands under Medicare coverage. Connectivity will become standard, and vendors without cloud-based device management will lose tender positions.

Competitive structure will shift toward platform vendors that combine hardware with monitoring, service and remote diagnostics. Philips Respironics' return to full U.S. sales after its consent decree compliance window will reshape home-care share, while Mindray's growth will depend on tariff outcomes. Hospital systems will consolidate purchasing further, rewarding suppliers that deliver total-cost-of-ownership guarantees.